【摘要】 目的探讨依贝沙坦对扩张型心肌病患者的心室重塑和心功能的影响。方法扩张型心肌病患者141例,随机分为两组。对照组69例,常规治疗;治疗组72例,在常规治疗的基础上给予依贝沙坦150mg/d。两组均连续观察1年。治疗前和治疗后6个月及1年,用美国ALT公司HDI3000彩色多普勒超声诊断仪测定左室心肌质量(LVMV)、左室射血分数(LVEF)和左室后壁收缩期增厚率(△T%)等参数,以评价依贝沙坦对扩张型心肌病患者的心室重塑和心功能的影响。结果(1)LVMV的变化:治疗组治疗后6个月减少5.58%(P<0.05),1年时减少9.39%(P<0.01);对照组治疗前后无显著变化。(2)LVEF的变化:治疗组治疗后6个月上升6.03%(P<0.05),1年时上升18.34%(P<0.01),对照组治疗前后无显著变化。(3)△T%的变化:治疗组治疗后6个月和1年时上升7.96%和19.72%(P<0.01),对照组治疗前后无显著变化。结论依贝沙坦能明显改善扩张型心肌病患者的心室重塑和左室收缩功能。更多还原

【Abstract】 Objective To evaluate the effects of irbesartan on reverse ventricular remodeling and improvement of cardiac function in dilated cardiomyopathy patients Methods The study was designed as a randomized,control trial One hundred and forty one patients with dilated cardiomyopathy were divided into two groups(sixty nine patients in control group and seventy two patients in irbesartan group ) receiving routine therapy or routine therapy plus irbesartan(150 mg once a day) for 1year The data of ventricular function and remodeling(including LVMV,LVEF and △T%) were measured by echocardiography in the DCM patients at baseline,6 and 12 months after treatment Results (1)In irbesartan group,LVMV decreased 5 58%at 6 month compared with that at baseline(P< 0 05) and it did 9 39%at 12 month compared with that at baseline(P<0 01),but there was no significant differences in control group;(2)In irbesartan group,LVEF increased 6 03%at 6 month compared with that at baseline(P< 0 05) and it did 18 34%at 12 month compared with that at baseline(P<0 001),but there was no significant differences in control group;(3)In irbesartan group,△T%increased 7 96%at 6 month compared with that at baseline(P< 0 01) and it did 19 72%at 12 month compared with that at baseline(P< 0 001),but there was no significant differences in control group Conclusions Irbesartan reverses ventricular reverses ventricular remodeling and improves ventricular remodeling and improves cardiac function in patients with dilated cardiomyopathy更多还原